BSX

AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX

Retrieved on: 
Tuesday, February 27, 2024

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX).
  • Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon

Retrieved on: 
Friday, March 1, 2024

MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

Key Points: 
  • First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence
    MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
  • ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9029352-boston-scientific-fda-ap...
    "With more than 100,000 patients treated globally to date in both clinical and commercial settings, we are very pleased to introduce this proven therapy as the first drug-coated coronary balloon in the U.S," said Lance Bates, president, Interventional Cardiology Therapies, Boston Scientific.
  • Boston Scientific plans to launch the technology in the U.S. in the coming months.

MIAX Named Best Trading Platform at the Fund Intelligence Operations and Services Awards 2024

Retrieved on: 
Thursday, February 22, 2024

PRINCETON, N.J., Feb. 22, 2024 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that MIAX has been named the "Best Trading Platform" at the Fund Intelligence Operations and Services Awards 2024.

Key Points: 
  • PRINCETON, N.J., Feb. 22, 2024 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that MIAX has been named the "Best Trading Platform" at the Fund Intelligence Operations and Services Awards 2024.
  • "We are honored to be recognized for the second year in a row as recipients of the award for 'Best Trading Platform,'" said Thomas P. Gallagher, Chairman and Chief Executive Officer of MIAX.
  • Since 2016, MIAX has been named a winner every year at the Fund Intelligence Operations and Services Awards.
  • MIAX won the "Most Innovative Technology" for the years 2017 through 2020, received the "Best Options Trading Platform" award for 2021, and the "Best Trading Platform" award for 2022.

MIAX Named Best Trading Platform at the Fund Intelligence Operations and Services Awards 2024

Retrieved on: 
Thursday, February 22, 2024

PRINCETON, N.J., Feb. 22, 2024 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that MIAX has been named the "Best Trading Platform" at the Fund Intelligence Operations and Services Awards 2024.

Key Points: 
  • PRINCETON, N.J., Feb. 22, 2024 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that MIAX has been named the "Best Trading Platform" at the Fund Intelligence Operations and Services Awards 2024.
  • "We are honored to be recognized for the second year in a row as recipients of the award for 'Best Trading Platform,'" said Thomas P. Gallagher, Chairman and Chief Executive Officer of MIAX.
  • Since 2016, MIAX has been named a winner every year at the Fund Intelligence Operations and Services Awards.
  • MIAX won the "Most Innovative Technology" for the years 2017 through 2020, received the "Best Options Trading Platform" award for 2021, and the "Best Trading Platform" award for 2022.

Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference

Retrieved on: 
Monday, February 5, 2024

MARLBOROUGH, Mass., Feb. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6, 2024.

Key Points: 
  • MARLBOROUGH, Mass., Feb. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6, 2024.
  • Mike Mahoney, chairman and chief executive officer, will participate in a 30-minute question-and-answer session with the host analyst at approximately 9:10 a.m.
  • A live webcast of the session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com .
  • The replay will be available approximately one hour following the completion of the event.

Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System

Retrieved on: 
Wednesday, January 31, 2024

MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment.

Key Points: 
  • Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system
    MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System.
  • "The approval of the FARAPULSE PFA System marks an important milestone for the millions of people living with paroxysmal AF and is an incredible opportunity to bring the first PFA system designed and built solely for this type of ablation therapy to physicians in the U.S.," said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific.
  • The FARAPULSE PFA System, however, relies on tissue-selective, non-thermal electric fields to ablate heart tissue and avoid damage to surrounding structures.
  • The company is developing a navigation-enabled version of the FARAWAVE catheter alongside the FARAVIEW™ Software Module and anticipates regulatory approval in 2024.

Miami International Holdings Appoints Kelly Brown as Senior Vice President Derivatives Products and Business Development for MIAX Futures

Retrieved on: 
Friday, January 19, 2024

PRINCETON, N.J., Jan. 19, 2024 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that Kelly Brown has joined the company as Senior Vice President Derivatives Products and Business Development for MIAX Futures.

Key Points: 
  • PRINCETON, N.J., Jan. 19, 2024 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that Kelly Brown has joined the company as Senior Vice President Derivatives Products and Business Development for MIAX Futures.
  • In this newly created position, Mr. Brown will be responsible for developing and maintaining strategic relationships with futures commission merchants, broker dealers and clearing members across the global futures industry.
  • Mr. Brown joins MIAX after serving as Senior Principal, Head of Derivatives for Gemini Trust Company where he managed the build-out of its trading platform.
  • "I have been fortunate in my career to hold roles at the forefront of financial innovation, which is embedded in MIAX's culture and DNA," said Kelly Brown, Senior Vice President, MIAX Futures.

Miami International Holdings Appoints Kelly Brown as Senior Vice President Derivatives Products and Business Development for MIAX Futures

Retrieved on: 
Friday, January 19, 2024

PRINCETON, N.J., Jan. 19, 2024 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that Kelly Brown has joined the company as Senior Vice President Derivatives Products and Business Development for MIAX Futures.

Key Points: 
  • PRINCETON, N.J., Jan. 19, 2024 /PRNewswire/ -- Miami International Holdings, Inc. (MIH), owner of Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire, LLC (MIAX SapphireTM), Minneapolis Grain Exchange, LLC (MGEXTM), LedgerX LLC (LedgerX), The Bermuda Stock Exchange (BSX), and Dorman Trading, LLC (Dorman Trading), today announced that Kelly Brown has joined the company as Senior Vice President Derivatives Products and Business Development for MIAX Futures.
  • In this newly created position, Mr. Brown will be responsible for developing and maintaining strategic relationships with futures commission merchants, broker dealers and clearing members across the global futures industry.
  • Mr. Brown joins MIAX after serving as Senior Principal, Head of Derivatives for Gemini Trust Company where he managed the build-out of its trading platform.
  • "I have been fortunate in my career to hold roles at the forefront of financial innovation, which is embedded in MIAX's culture and DNA," said Kelly Brown, Senior Vice President, MIAX Futures.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Retrieved on: 
Tuesday, January 16, 2024

BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Butterfield Announces Senior Management Appointments

Retrieved on: 
Monday, January 15, 2024

Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced the promotion of Michael Neff to Group Chief Operating Officer.

Key Points: 
  • Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced the promotion of Michael Neff to Group Chief Operating Officer.
  • Mr. Neff, who has served as Managing Director of Bermuda and International Wealth since 2018 having joined Butterfield in 2011 as Group Head of Asset Management, takes responsibility for operations and technology across the Group.
  • At RiskMetrics, he initially served as Global Head of Wealth Management rising to become Co-Head of the firm’s Global Financial Risk Management business.
  • Mr. Dallas has extensive experience in marketing strategy and customer-led growth, and has led the marketing and communications functions at Butterfield since 2020.